(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
A definitive Burger Confrontation: Which One Rules? - 2Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge
- 3Dark matter may be made of pieces of giant, exotic objects — and astronomers think they know how to look for them
- 4Science is best communicated through identity and culture – how researchers are ensuring STEM serves their communities
- 5Careful Connections: Building Association and Trust
- Manual for Tracking down the Mysterious Cascades in China
- Miss 'Stranger Things' already? Here's how you can get your Upside Down fix in 2026 with spinoffs, games and more
- Insane Realities That Will Make You Reconsider How you might interpret History
- Pick Your Number one Sort Of Music
- Remain Fit: Powerful Wellness and Work-out Schedules for a Better You
- Manual for Individual accounting Rudiments for Fledglings
- Manual for Picking the Ideal Wine Matching
- 25 Years Ago, Audi's Rosemeyer Concept Was A Steampunk Supercar With A Massive Engine
- Watching ‘Home Alone’ with the kids this holiday season? Brace yourself for '6-7.'
